FA (Fanconi anaemia) is a rare hereditary disorder characterized by congenital malformations, progressive bone marrow failure and an extraordinary predisposition to develop cancer. At present, 15 genes have been related to this condition and mutations of them have also been found in different types of cancer. Bone marrow failure threatens the life of FA patients during the first decade of their life, but the mechanisms underlying this process are not completely understood. In the present study we investigate a possible imbalance between the expression of proand anti-apoptotic proteins as a cause for the hypersensitivity of FANCC (FA, complementation group C)-deficient cells to genotoxic stress. We found a BIK (Bcl-2 interacting killer) over-expression in lymphoblastoid cell lines derived from FA-C patients when compared with their phenotypically corrected counterparts. This overexpression has a transcriptional basis since the regulatory region of the gene shows higher activity in FANCC-deficient cells. We demonstrate the involvement of BIK in the sensitivity of FA-C lymphoblasts to interstrand DNA cross-linking agents as it is induced by these drugs and interference of its expression in these cells preserves their viability and reduces apoptosis. We investigate the mechanism of BIK overexpression in FANCC-deficient cells by analysing the activity of many different signalling pathways in these cells. Finally, we provide evidence of a previously undescribed indirect epigenetic regulation of BIK in FA-C lymphoblasts mediated by Np73, an isoform of p73 lacking its transactivation domain that activates BIK through a proximal element in its promoter.
INTRODUCTION
FA (Fanconi anaemia) is a recessive congenital disorder caused by mutations in any of 15 different FANC genes that define 15 different complementation groups [1] . Clinically it is characterized by congenital malformations, progressive bone marrow failure and an extraordinary high predisposition to suffering cancer, mainly haematological, but also solid tumours [2] . Sporadic mutations in FANC (FA gene) have also been found in other types of cancer [3] . A progressive thrombocytopenia and eventually pancytopenia is usually the first clinical manifestation that, added to the physical alterations, raises the suspicion of an FA diagnosis. Although there has been great advances in the treatment of the bone marrow degradation of these patients, the drugs used sometimes have undesirable side effects and when an HSC (haemopoietic stem cell) transplantation is needed, it is not always possible to find a suitable donor. Thus the increase in our knowledge on the mechanisms underlying this failure will help in the development of new treatments. Several studies have shown an elevated predisposition of FA haemopoietic progenitors to apoptosis and this is thought to be the cause of the bone marrow aplasia in these patients [4] . This inherited predisposition is enhanced by the elevated production of certain inhibitory cytokines in these patients [5] as well as by oxidative stress [6] and by the exposure to environmental genotoxic agents, to which FA cells are particularly sensitive [7, 8] . However, the pathways involved in the apoptosis predisposition of FA cells are still not fully understood.
BH3 (Bcl-2 homology domain 3)-only proteins are proapoptotic members of the family of proteins defined by their homology to Bcl-2. BIK (Bcl-2-interacting killer) was the first member where the apoptotic activity was linked to its BH3 domain [9, 10] . This domain is responsible for the interaction of BIK with anti-apoptotic proteins like Bcl-2 and Bcl-X. This interaction releases BAK (Bcl2-antagonist/killer) and BAX (Bcl-2-associated X protein), that mediate the liberation of cytochrome c from the mitochondria and its activation of caspases [11] . Thus BH3-only proteins are classified into two groups: activators [BIM (Bcl-2-interacting mediator of cell death), BID (BH3-interacting domain death agonist) and PUMA (p53 up-regulated modulator of apoptosis)], capable of directly activating BAX and BAK, and sensitizers [BIK/NBK, Bmf (Bcl-2-modifying factor), BAD (Bcl-2/Bcl-xL antagonist, causing cell death) and NOXA] [12] , that interact with and sequester the anti-apoptotic members of the Bcl-2 family, leaving the cells more sensitive to pro-apoptotic triggers. Alterations in BIK expression by many different mechanisms have been described in relation to carcinogenesis. BIK expression probably needs a tight regulation owing to its already exposed BH3 domain [13] . Mechanisms regulating BIK function include p53-dependent and independent transcriptional regulation by different factors including TEF (transcriptional enhancer factor) and
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E2F-1 [14, 15] , chromosomal deletions [16] , phosphorylation of the protein [17] and methylation of the gene regulatory region [18] . In haematological malignancies, BIK expression has been related to the busulfan sensitivity in myeloid leukaemia cells [19] and in the sensitivity to oxidative stress in myeloma cells [20] . In Burkitt's lymphoma B-cell lines, TGF-β (transforming growth factor β) induces apoptosis by transcriptionally activating BIK and repressing Bcl-xL [21] . BIK is also activated during the Bcell-receptor stimulation, a mechanism thought to mediate B-cell selection at the germinal centres [22] .
These features of BH3-only proteins make them ideal candidates to mediate the progressive bone marrow failure of FA patients. In the present study, we identify BIK as overexpressed in two LCLs (lymphoblastoid cell lines) derived from FA-C patients and demonstrate its implication in the sensitivity of these cells to interstrand DNA cross-linking agents. We also provide evidences of an epigenetic up-regulation of the expression of BIK in these cells, that uncovers a new regulation of BIK by Np73.
MATERIALS AND METHODS

Cell culture and cell viability assay
EBV (Epstein-Barr virus)-transformed human lymphoblasts were maintained in RPMI 1640 media (Life Technologies) supplemented with 10 % heat-inactivated fetal bovine serum and grown in a humidified 5 % CO 2 -containing atmosphere at 37
• C. The FANCC-deficient cell lines EUFA450 (heterozygous for 322delG and L554P) and HSC536, and their phenotypically corrected counterparts, have been described previously [23] . Cells were grown in the presence of LY294002 (Cayman), NAC (N-acetylcysteine) (Sigma), TGF-β (Life Technologies), IFNγ (interferon γ ; Applichem), Imatinib (Novartis), Tacrolimus (FK506) (Astellas) or DCB (5-aza-2 -deoxycytidin/Decitabine; Santa Cruz Biotechnology) where indicated. shRNA (shorthairpin RNA) viral vectors (Sigma) were transduced into the cells to interfere with the expression of the indicated genes. Stably shRNA-transduced cells were selected by incubation with puromycin (Applichem). To determine the cell resistance to certain treatments, 50 000 cells were plated on 96-well plates and incubated for 3 days in the presence of the indicated drugs. Cell viability was then determine using the XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] Cell Proliferation kit II (Roche) following the manufacturer's instructions.
RT (reverse transcription)-PCR analysis
Total RNA was prepared using TRI Reagent (Molecular Research Center). To assess mRNA expression, a semi-quantitative RT-PCR method was used. For the RT reaction, RNA (5 μg) was primed with random hexamers and reverse transcribed with Superscript MMLV (Maloney murine leukaemia virus) reverse transcriptase (Invitrogen) in a 20 μl volume following the manufacturer's instructions. The generated cDNA was amplified using the primers: human BIK (forward, 5 -GACCATGGAGG-TTCTTGGCA-3 and reverse, 5 -AGGCTCACGTCCATCTCGT-C-3 ), PUMA (forward, 5 -ACGACCTCAACGCACAGTACG-3 and reverse, 5 -TGGGTAAGGGCAGGAGTCC- (25 cycles) , the expected PCR products were size-fractionated on a 2 % agarose gel and stained with ethidium bromide.
Western blot analysis
To prepare whole-cell lysates, cells were collected by centrifugation (1200 g for 5 min at 4
• C), washed once with PBS and then lysed in EBC buffer [50 mM Tris/HCl (pH 8.0), 120 mM NaCl and 0.5 % Nonidet P 40] supplemented with aprotinin (11.5 μg/ml), leupeptin (11.5 μg/ml), PMSF (50 μg/ml), NaF (100 mM) and sodium orthovanadate (0.2 mM). Protein concentration was determined by BCA (bicinchoninic acid) following the manufacturer's instructions (Pierce). Proteins (100 μg) were resolved by SDS/PAGE (10 % gel) and transferred on to PVDF filters. Blots were incubated with rabbit antibodies against BIK, p53, DNMT1 (DNA methyltransferase 1) or GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Santa Cruz Biotechnology) and then incubated with anti-rabbit, antimouse or anti-goat antibodies conjugated with horseradish peroxidase (Pierce). The bound antibodies were detected by a chemiluminescence assay (Pierce).
Gene reporter assay
A genomic PCR fragment of 1038 bp ( − 998 to + 40, referred to as the initiation of transcription) from the 5 regulatory region of BIK was amplified with specific primers and cloned into the pGL2basic luciferase reporter vector (Promega). Deletions of this original construct were obtained by amplification using specific primers and cloning into pGL2basic. Similarly, a 1 kb sequence upstream of the transcription start site of Np73 corresponding to the second promoter of the p73 gene, was amplified from human genomic DNA and cloned into the same reporter vector. The cells were co-transfected with 1 μg of the reporter constructs, 2 μg of the adequate expression vectors and 0.2 μg of pEF-BOS-β-galactoside in triplicate using Superfect (Qiagen) according to the manufacturer's instructions. At 36 h after transfection, cell extracts were prepared and analysed for their luciferase activity by using a reporter gene assay system (Promega). The results were normalized for transfection efficiency with the β-galactosidase activity values obtained in the same extracts.
Methylation analysis
Genomic DNA was isolated using DNAzol ® reagent (Invitrogen). A total of 1 μg of genomic DNA was modified with bisulfite using the EZ DNA Methylation Gold kit (Zymo Research). The region between − 314 and + 44 of the BIK promoter was amplified with the primers 5 -AAAGGGTTAGATTTTGTTAATGGAT-3 (forward) and 5 -ATACTAACAACGTCTATAAACCACC-3 (reverse), and cloned into the plasmid pCR-II by TA cloning (Invitrogen). The plasmids were transformed into DH5-alfa bacteria and ten different colonies from each cell line were sequenced. For the analysis of the methylation of the second promoter of p73 (P2p73), 1 μg of genomic DNA from the indicated cell lines was digested overnight with HpaII, MspI or with no enzyme. After inactivation of the enzymes at 65
• C for 20 min, the integrity of the P2p73 under each digestion was determined by PCR with the primers 5 -GAAAGCAGGCAG-GTGGTTTGGG-3 (forward) and 5 -TGAATCCAACAACAA-AACCCGC-3 (reverse), that amplify 1 kb upstream of the transcription start site.
RESULTS
BIK is overexpressed in FANCC-deficient cell lines
It is well known that FA-C cells are hypersensitive to interstrand DNA cross-linking agents like cisplatin or MMC (mitomycin C). We hypothesized that such an increased sensitivity could eventually be due to the aberrant expression of genes directly involved in the apoptotic response, whose final misbalance leave the FA cells prone to apoptosis. In order to avoid the influence of the genetic background, we used an isogenic model of an LCL derived from an FA-C patient and its counterpart line, corrected by a second mutation that restores the functionality of the FANCC protein. We analysed the basal expression of a number of apoptotic genes in these two cell lines. Although we did not observe much variation in the expression of most of the genes analysed, the overexpression of BIK and PUMA in FA-C cells correlated well with their apoptosis-prone phenotype ( Figure 1A ). We validated these results by quantitative RT-PCR analysis of four pro-apoptotic genes in the same cells: PUMA, BAX, NOXA and BIK. The test confirmed that BIK and PUMA mRNAs accumulated at a much higher basal level in FA-C cells ( Figure 1B ). Quantitative analysis of these mRNAs in a second FANCC-deficient lymphoblastoid cell line showed similar results when compared with their corrected counterparts transduced with a wild-type FANCC expression vector ( Figure 1C ). BIK protein mirrored the level of BIK mRNA in FA-C LCLs as shown by Western blotting ( Figure 1D ). Moreover, BIK mRNA accumulated at a higher level also in a SCC (squamous cell carcinoma) cell line derived from an FA-C patient when compared to its FANCC-transduced counterpart or to another SCC cell line derived from an FANC-proficient patient ( Figure 1E ). We could not detect similar differences in BIK mRNA accumulation between FANCA-deficient cells and their corrected isogenic controls (Supplementary Figure S1F at http://www.BiochemJ.org/bj/448/bj4480153add.htm). Since BIK was consistently overexpressed in the cell lines tested, we focussed our efforts on the characterization of the molecular mechanisms leading to its activation in FANCC-deficient cells and its role in the apoptosis-prone phenotype of these cells.
The BIK gene promoter is more active in FA-C LCL
We then explored a potential transcriptional mechanism as responsible of the overexpression by transfecting a reporter construct containing 556 bp of the region upstream of the transcriptional initiation of the gene into FA-C LCLs or their reverted controls. This region was able to promote the transcription of the reporter gene in FANCC-proficient cells, although at a very low rate as expected for a gene involved in cellular death ( Figure 2A ). The activity of this promoter region was clearly higher when transfected into FANCC-deficient cells (Figure 2A ), suggesting a transcriptional mechanism in the overexpression of BIK in FA-C cells. In order to ascertain a role of FANCC deficiency in the activation of the BIK promoter, we transfected the reporter construct into the HCT116 colon carcinoma cell line, and co-transfected a shRNA interference plasmid against FANCC. As shown in Figure 2(B) , the interference of FANCC expression produced an activation of the BIK promoter in these cells. Moreover, when we artificially overexpressed FANCA in HCT116 cells, the activity of the BIK promoter reporter construct notably reduced ( Figure 2C ). These data further confirm a role of FANCC in the transcriptional regulation of BIK.
BIK expression is activated during genotoxic-induced cell death in FA-C LCL
Cisplatin and MMC are drugs known to create adducts between the DNA strands that the FA cells fail to resolve properly leading to an aberrant induction of the apoptosis mechanisms, which is considered a hallmark of this pathology. We tested our isogenic model by treating the cells with increasing concentrations of cisplatin and determining the cell viability after 3 days. FANCCdeficient cells showed reduced viability at lower cisplatin doses than their corrected isogenic partners, as expected ( Figure 3A) . Something similar happened when we treated FA-C cells with MMC (results not shown).
BIK is a well-known BH3-only protein involved in the apoptotic response to chemotherapeutic agents [15] . In order to determine whether this gene plays a role in the stronger response of FANCC-deficient cells to interstrand DNA crosslinking agents we studied the accumulation of its mRNA after cisplatin treatment. After a 24 h incubation of FA-C LCLs with cisplatin at doses that differentially affect their viability compared with FANC-proficient cells (see Figure 3A) , we observed a dose-dependent accumulation of the BIK transcript in both cell types, but the levels they reached were clearly higher in FANC-deficient cells ( Figure 3B ). Other apoptosis-related genes showed much milder increases in their mRNA if any. A similar induction of BIK expression was obtained when we incubated FA-C LCLs in the presence of MMC, both at the mRNA and protein levels ( Figure 3C ). Interestingly, p53 was strongly stabilized in response to MMC in these cells (Supplementary Figure S2C at http://www.BiochemJ.org/bj/448/bj4480153add.htm), mirroring BIK induction. A second FANCC-deficient LCL showed similar BIK inductions after MMC treatment when compared with its phenotypically corrected controls ( Figure 3D) .
These results show a differential induction of the BIK proapoptotic gene after DNA damage depending on FANCC integrity and suggests that BIK basal overexpression is a predisposition factor of FA-C cells to apoptosis.
Interference of BIK expression makes FA-C LCLs more resistant to cross-linking agents
To determine the role of BIK in the predisposition of FA-C cells to apoptosis, we genetically interfered with its expression using an shRNA construct and analysed the effect on the sensitivity of FA-C LCLs to interstrand DNA cross-linking agents. We obtained an FA-C cell line stably transfected with the BIK shRNA construct where we confirmed a 50% reduction in BIK mRNA expression ( Figure 4A ) that caused a reduction in BIK protein (results not shown). The interference of BIK in these FANCC-deficient cells preserves a higher viability in response to cisplatin in comparison with the parental cell line or cells transduced with a non-target shRNA construct ( Figure 4B) . Analysis of the cell cycle of these cells showed a reduction in the sub-G 1 -phase peak, representing the cells undergoing apoptosis, both basally or after treatment with cisplatin ( Figure 4C) . Similarly, the interference of BIK expression led to a reduction in the amount of propidium-iodidestained cells after cisplatin treatment ( Figure 4D ). Taken together, these data demonstrate a role for BIK overexpression in the hypersensitivity of FA-C cells to interstrand DNA cross-linking agents.
BIK basal activation in FA-C LCLs is not related to an elevation in DNA damage signalling
One possible explanation for the high basal levels of BIK mRNA in FA-C LCLs could be that the failure in their DNA repair machinery leads to an accumulation of DNA damage and to a basal activation of the apoptotic pathways in these cells. To test this possibility, we decided to block ROS (reactive oxygen species) and the activation of the tyrosine kinase c-Abl, both mediators of DNA damage signalling [24] [25] [26] , in FA-C LCLs and analyse the effect on BIK expression. Pre-treatment of FA-C with the antioxidant NAC prior to the addition of cisplatin completely blocked BIK mRNA induction ( Figure 5A ), indicating a role for ROS in this process. However, although capable of reducing basal BIK expression in corrected LCLs, NAC had no effect on the basal levels of BIK mRNA in FANCC-deficient LCLs, suggesting that its basal increase is not due to the accumulation of ROS in FANCC-deficient cells ( Figure 5B ). Consistently, incubation of FA-C LCLs for 3 days with increasing concentrations of NAC did not affect their viability, as measured by the XTT assay ( Figure 5C ), and only slightly improved the viability of these cells when exposed to low doses of cisplatin ( Figure 5D ). As in the case of NAC, treatment with Imatinib, a specific inhibitor of cAbl, reduced the basal levels of BIK mRNA in FANCC-proficient cells in a dose-dependent manner ( Figure 5E ). Both observations suggest that basal expression of BIK in FANC-proficient cells is due to signals induced by DNA damage probably caused by errors in the DNA replication process. However, BIK mRNA expression in FA-C cells was unaffected by Imatinib treatment ( Figure 5E ), indicating that an elevated c-Abl activation is not the cause of the increased BIK expression in these cells. Moreover, the treatment with Imatinib had no effect on the viability of these cell in response to cisplatin (results not shown). Taken together, these data suggest that an increase in the DNA damage signalling is not the cause of the elevated basal BIK levels in FA-C LCLs.
Analysis of different signalling pathways that may regulate BIK in FA-C LCLs
Since an increase in DNA damage signalling does not seem to be involved in BIK overexpression in FA-C LCLs, we considered an aberrant activation of other signalling pathways as responsible for such an effect. BIK has been related to the induction of apoptosis in B-cells mediated by the B-cell receptor [22] . This activation of BIK is dependent of the PI3K (phosphoinositide 3-kinase) and calcineurin signalling pathways. We used specific inhibitors of these two pathways and analysed their effect on BIK mRNA levels in FA-C LCLs. The calcineurin inhibitor Tacrolimus did not affect BIK expression (Supplementary Figure S1A) ; however, PI3K demonstrated some activity over BIK expression since treatment with LY294002 moderately reduced the accumulation of BIK mRNA, although the effect was more evident in FANCCproficient cells (Supplementary Figure S1B) . This subtle effect was not accompanied by a clear change in cellular viability (Supplementary Figure S1C) . Inactivation of FANCC has been related to an increase in IFNγ -induced apoptotic responses in haemopoietic cells [23, 27] . However, incubation of our FA-C LCLs with increasing concentrations of IFNγ for 24 h had no effect on their viability (Supplementary Figure S1D) . Something similar happened when the cells were incubated with TGF-β, a cytokine known to induce apoptosis in human B-cells through the regulation of BIK and Bcl-X [21] (Supplementary Figure S1E) . In addition, these two cytokines induced no significant change in BIK mRNA in our cells (Supplementary Figures S1F and S1G ).
Demethylating agents induce BIK expression and sensitize control LCLs to interstrand DNA cross-linking agents
Several epigenetic events have been reported to modify BIK expression in relation to carcinogenesis [28] . Thus we considered a possible change in the methylation status of the BIK promoter as the reason for its elevated basal expression in FA-C cells. BIK mRNA expression is clearly induced in response to the demethylating agent DCB, especially in FANCC-proficient cells where BIK mRNA rises to reach the level observed in FA-C LCLs ( Figure 6A ). We then studied the methylation status of the BIK promoter in FANCC-deficient cells to try to correlate it with the basal expression level of the gene. However, the methylation analysis of 31 methylable CpG dimers between positions − 314 and + 44 of the gene showed a lack of methylation both in FA-C LCLs and their corrected controls (Supplementary Figure  S2A) . To investigate a possible indirect epigenetic effect on BIK basal expression, we then studied the expression profile of factors candidate to regulate BIK in response to demethylating agents. We found that Np73, an isoform of p73 driven by a second promoter within the third intron of the gene, is clearly induced both by DCB and MMC, following a pattern very similar to that of BIK ( Figure 6A ). In clear contrast, the mRNAs of the closely related genes TAp73 and p53 showed no change in response to DCB. Quantitative RT-PCR further confirmed a higher basal expression of Np73 in FA-C LCLs (Supplementary figure 2B) , suggesting a relationship between these two genes. To investigate a possible transcriptional regulation of BIK by Np73, we analysed the effect of this on the activation of the BIK gene promoter. In cotransfection experiments, Np73 was able to induce 2-fold the Genomic DNA extracted from these cells was digested with the methylation-sensitive restriction enzyme HpaII (H), the methylation-insensitive restriction enzyme MspI (M) or no enzyme (U) and the first kb region of the promoter was amplified using specific primers. (E) Decitabine sensitizes control LCLs to MCC. HSC536 (FA-C, ᭺) and their wild-type FANCC-transduced controls (ᮀ) were treated with increasing concentrations of MMC in the absence (solid lines) or presence (broken lines) of 10 μM DCB. Viability was measured using an XTT cell viability assay.
luciferase activity driven by the region between positions − 998 and + 40 relative to the transcription start site of the BIK gene ( Figure 6B ). p53 does not directly activate the BIK promoter, although strongly activates promoter 2 of p73, responsible for the regulation of Np73 transcription in the cell. The element within the BIK promoter responsible for its induction by Np73 seems to be located between positions − 96 and the transcriptional start site, since deletion of the promoter further than that abrogates both its basal activity and its induction by Np73 ( Figure 6C ). Analysis of promoter 2 of p73 with methylation-sensitive restriction enzymes revealed a lower methylation level in FA-C LCLs compared with their corrected counterparts, compatible with the higher basal expression of Np73 in these cells ( Figure 6D ). This group of results demonstrate that FA-C LCLs show alterations in their DNA methylation pattern that lead to the basal overexpression of BIK through its regulation by Np73.
Since DCB induces the expression of BIK in FANCC-proficient cells, we wanted to test whether this induction sensitizes these cells to DNA ICL (interstrand cross-linking) agents. Thus we treated both FA-C and reverted LCLs with DCB and analysed the response of the cells to MMC. Treatment with DCB induced no noticeable change in the sensitivity of FANCC-deficient cells to MMC. However, FANCC-proficient cells became more sensitive to MMC, showing a viability curve similar to that of FA-C LCLs ( Figure 6E ). These data further support the idea that BIK mediates the sensitivity of FA-C to DNA ICL agents and that its higher basal expression in FA-C LCLs though epigenetic mechanisms leave the cells prone to apoptosis.
DISCUSSION
One of the main cellular aspects of the phenotype of FA is the predisposition both spontaneous and induced to programmed cell death or apoptosis. This predisposition is behind the progressive bone marrow failure of these patients. This aspect of the pathology is an important issue since it threatens the life of the patient within the first decade of life. Current therapies for this bone marrow failure have important side effects and, in the case of transplantation, adds the problem of finding a suitable bone marrow donor. Thus preservation of the haemopoietic progenitors of these patients is of extreme importance. The knowledge of the mechanisms and cellular components involved in the predisposition to apoptosis of FANC-deficient cells become then crucial to develop new therapies with lower side effects and that may avoid more aggressive treatments.
In the present study we identified apoptosis-related genes with altered basal expression that could account for the elevated predisposition to apoptosis of FA-C cells. Our discrete screening in an isogenic LCL model identified BIK as being consistently overexpressed in FA-C LCLs at the mRNA basal level. This gene codes for a BH3-only protein known to activate other executive members of the same family, namely BAX and BAK. BH3-only proteins can be divided into those that directly activate BAX and BAK, and those that sensitizes cells by releasing them from the dimers they form with anti-apoptotic Bcl-2-related proteins [12] . BIK belongs to the sensitizers of BH3-only family. Thus the overexpression of BIK seems to be related to the sensitivity of these cells to DNA cross-linking agents. In agreement with this idea, the interference of BIK expression using short hairpin constructs make FANCC-deficient LCLs more resistant to cisplatin ( Figure 4B ) and reduces the number of cells entering apoptosis under these conditions ( Figures 4C and 4D) .
In the present study we provide for the first time evidence of a role of FANCC in the modulation of BIK expression. Surprisingly, BIK basal overexpression does not seem to be related to the accumulation of DNA damage in FA-C LCLs since an antioxidant such as NAC or the inhibition of c-Abl, known to mediate DNA damage signals, only blocked the cisplatin-induced activation of BIK, but had no effect on its basal mRNA levels in FA-C cells ( Figure 5 ). BIK gene expression is very tightly controlled owing to its exposed BH3 domain [13] . Several mechanisms of BIK regulation have been described in relation to carcinogenesis [14] [15] [16] [17] [18] . We explored several pathways related to B-cell physiology as possible aberrant mediators of BIK overexpression in FA-C cells, but we found no clear involvement in our system (Supplementary Figure S1) .
FA haemopoietic stem cells have been reported to be more sensitive to inhibitory cytokines [23, 29] that, in addition, are overexpressed by FA patients [30, 31] . Some authors give central importance to cytokines in the aetiology of bone marrow failure in FA. However, treatment of LCLs with either IFNγ or TGF-β have no effect on cell viability or did not induce any change in BIK expression, independently of their FANCC status (Supplementary figures S1D-S1G). This lack of response to IFNγ or TGF-β in LCLs could be attributable to the interference of the EBV used for the immortalization of the cells.
Changes in the methylation pattern of tumour suppressor genes have been associated with carcinogenesis. BIK has been identified as one of the most affected genes by epigenetic mechanisms in cancer cells [18, 28] and it actually contains a CpG island in its promoter region that makes it susceptible to regulation by methylation. We hypothesized that the elevated levels of expression of BIK in FA-C LCLs could be due to a demethylation of its regulatory region. This idea was supported by our finding that a demethylating agent can increase BIK mRNA expression in control LCLs to reach levels similar of those of FANC-deficient cells ( Figure 6A ). Moreover, treatment with DCB induces a concomitant increase in the sensitivity of FANCC-proficient cells to MCC, supporting the idea that BIK contributes to the apoptosisprone phenotype of FA-C cells ( Figure 6E ). However, 31 CpG dimers within the first 314 bp of the 5 upstream region of the BIK gene are completely unmethylated in LCLs irrespective of their FANCC status. This observation correlates with the data of Milutinovic et al. [32] showing a predominantly unmethylated pattern of this gene. These authors demonstrated a regulation of BIK by DNMT1 independently of their methylase function. Interestingly, DNMT1 knock down induces a stress cellular response with a gene expression profile very similar to that of FA cells ( [33] and Prieto-Remón, I., Sanchez-Carrera, D., López-Duarte, M., Richard, C. and Pipaón, C., unpublished work), and we previously demonstrated an altered methylation pattern of the first p73 intron in FANCA-deficient cells [34] , suggesting and interrelation between DNA methylation and repair pathways.
We then explored an indirect epigenetic regulation of BIK expression in FA-C LCLs. Although p53 has been related to the induction of BIK expression [35] and the BIK promoter contains degenerate p53-binding sites [36] , no response to p53 in promoter assays has been detected [35, 37] . In addition to this, several groups have reported p53-independent activation of the BIK gene in response to genotoxic chemotherapeutic drugs [15] . p53 is strongly stabilized at the protein level after MMC treatment, especially in FA-C LCLs, correlating with the activation of BIK mRNA expression. However, our promoter experiments indicate that it is Np73 and not p53 which is the member of the p53 family that activates the BIK promoter. Np73 is a truncated form of p73 that lacks its TA domain and is induced by p53 through its promoter, located in intron 3 of the p73 gene. Np73 has been reported to play dominant-negative functions with TAdomain-containing members of the family, but it also activates transcription through its interaction with other factors [38] . Our promoter deletion experiments locate the Np73-responsive element within the first 96 bp of the BIK promoter. The region between − 96 and − 40 contains SP1 (specificity protein 1)-binding sites that sustain the basal activity of this promoter in our experiments. A possible co-operation between SP1 and Np73 in the regulation of this promoter is currently under investigation in our laboratory.
Epigenetics are considered as a master regulator of Np73 mRNA expression [39] , and our data with demethylating agents further support this idea. We show a lower methylation degree of the second promoter of p73, that correlates with the higher basal expression of Np73 in FA-C LCLs. Thus our results point to Np73 as a key modulator of cell death mediated by BIK in FA-C cells, compiling both epigenetic and genotoxic-induced signalling. Alterations in both of these pathways in FANCCdeficient cells explain both basal and induced expressions of BIK, and so the apoptosis-prone phenotype of these cells.
In summary, we have reported an overproduction of BIK in FA-C LCLs and provided evidence of its implication in the FA-C apoptosis-prone phenotype. Our tests demonstrate an involvement of Np73 protein in BIK regulation, that mediates its activation both by genotoxic damage and epigenetic alterations in FA-C LCLs. Although further studies are needed, these findings open new therapeutic targets to alleviate the bone marrow aplasia of these patients.
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